Embed Size (px)
DESCRIPTION
Pre-treatment. Post-treatment. II. I. Pt #1. EGFR-del19. EGFR-del19-T790M. (Nuclear β -catenin 21.8%). (51.3 %). III. IV. Pt # 2. EGFR-L858R. EGFR-L858R-T790M. (4.0%). (20.7%). V. VI. Pt # 3. EGFR-del19. EGFR-del19-T790M. (3.8 %). (34.4%). VII. VIII. Pt # 4. EGFR-L858R. - PowerPoint PPT Presentation
Citation preview
Pt # 2
Pre-treatment
Pt # 3
EGFR-L858R EGFR-L858R-T790M
EGFR-del19 EGFR-del19-T790M
III IV
EGFR-L858R EGFR-L858R-T790M
Pt # 4
Supplementary Figure S2. Expression of β-catenin in pre- and post-EGFR TKIs lung biopsies.
(4.0%) (20.7%)
(3.8%) (34.4%)
(35.0%) (38.9%)
VIV
VII VIII
EGFR-del19 EGFR-del19-T790M
Pt #1
(Nuclear β-catenin 21.8%) (51.3%)
Post-treatment
III
